Description

Ipamorelin – 5 mg

(Selective Growth Hormone Secretagogue – GHSR Agonist)

Ipamorelin is a synthetic pentapeptide belonging to the growth hormone releasing peptide (GHRP) family. It functions as a selective ghrelin receptor (GHS-R1a) agonist, stimulating the pituitary gland to release endogenous growth hormone (GH) while exhibiting minimal impact on cortisol or prolactin levels.

Distinguished by its high selectivity and mild physiological profile, Ipamorelin is frequently used in research as a refined model for exploring GH modulation, cellular repair, and anabolic metabolism without the unwanted side effects observed in earlier GHRPs.

---

Mechanism of Action (Based on Preclinical and Clinical Research):

• Ghrelin receptor activation: Binds to GHS-R1a receptors, inducing natural GH pulse release.

• Selective GH stimulation: Triggers growth hormone secretion without significantly altering ACTH, cortisol, or prolactin.

• Synergistic interaction: Demonstrates additive GH release when combined with GHRH analogs (e.g., CJC-1295).

• Anabolic and metabolic support: Enhances protein synthesis and cellular repair processes in metabolic models.

• Neuroendocrine balance: Supports energy regulation and recovery through hypothalamic-pituitary modulation.

---

Potential Benefits (Based on Preclinical Research):

• Increased pulsatile GH and IGF-1 production

• Enhanced muscle recovery and protein synthesis

• Minimal effect on appetite and prolactin compared to GHRP-6 or Hexarelin

• Support for tissue regeneration and metabolic regulation

• Studied for potential applications in aging, repair, and hormone-regulation research

---

For Research Use Only. Not for Human Consumption.
This compound is not approved by the FDA or any regulatory agency and is intended solely for laboratory research.